Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Fennec Pharmaceuticals (FENC) over the last 12 years, with Q3 2025 value amounting to $1.5 million.

  • Fennec Pharmaceuticals' Change in Accured Expenses rose 43672.73% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $388000.0, marking a year-over-year decrease of 7236.47%. This contributed to the annual value of -$326000.0 for FY2024, which is 15659.72% down from last year.
  • Latest data reveals that Fennec Pharmaceuticals reported Change in Accured Expenses of $1.5 million as of Q3 2025, which was up 43672.73% from -$618000.0 recorded in Q2 2025.
  • Fennec Pharmaceuticals' 5-year Change in Accured Expenses high stood at $1.8 million for Q4 2023, and its period low was -$1.3 million during Q2 2024.
  • Its 5-year average for Change in Accured Expenses is $122937.5, with a median of -$144000.0 in 2021.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 135272.73% in 2021, then tumbled by 166666.67% in 2024.
  • Quarter analysis of 5 years shows Fennec Pharmaceuticals' Change in Accured Expenses stood at $689000.0 in 2021, then soared by 164.88% to $1.8 million in 2022, then increased by 1.1% to $1.8 million in 2023, then tumbled by 93.77% to $115000.0 in 2024, then surged by 1183.48% to $1.5 million in 2025.
  • Its Change in Accured Expenses was $1.5 million in Q3 2025, compared to -$618000.0 in Q2 2025 and -$585000.0 in Q1 2025.